BridgeBio Pharma currently markets the ATTR-CM treatment Attruby, which has been on a strong sales trajectory since its 2024 approval. (iStock/Getty Images Plus) BridgeBio Pharma is teaming up with ...
In ATTR amyloidosis, a buildup of harmful proteins causes damage to tissues and organs throughout the body, including the heart. Over time, the condition can progress from stage 1, which may cause ...
Genetic testing is an important part of the diagnosis process for transthyretin cardiac amyloidosis (ATTR-CM). It’s not only key to managing your care but also helps you determine whether others in ...
Advanced disease progression occurred less often with vutrisiran than placebo in both the overall population (8.0% vs 10.7%) and monotherapy subgroup (8.2% vs 11.1%). Transition to NYHA class IV was ...
Based on market patterns in other diseases such as pulmonary arterial hypertension and atrial fibrillation, Alnylam believes that the entire ATTR-CM category is still in its infancy. (iStock / Getty ...
Is rhythm control underused in ATTR-CM? Drs Kevin Alexander and Ronald Witteles make the case for rethinking how we manage arrhythmias in this disease. Is rhythm control underused in ATTR-CM? Drs ...
Drs Kevin Alexander and Joban Vaishnav explore when and how to use genetic testing in ATTR-CM, why distinguishing hereditary from wild-type disease matters, and what this means for patients' families.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier ...
His voice is easily among the most recognizable in the world. Award-winning actor Morgan Freeman has a presence that can command a room without stepping into it. On and off screen, his steady baritone ...
Life expectancy for people with ATTR amyloidosis varies, generally ranging from 3 to 15 years after symptoms appear, and depends on the specific type of the condition and any other health issues a ...
Vutrisiran reduced mortality and cardiovascular events in ATTR-CM patients across all age groups, including those aged 80 and older. The HELIOS-B trial demonstrated consistent benefits in reducing all ...
ATTR-CM can be a life-changing diagnosis, and if you’re an older adult, it can have an especially large impact on your quality of life. Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a rare but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results